Actuate therapeutics reports positive biomarker and machine learning data from phase 2 elraglusib trial in first-line treatment of metastatic pancreatic cancer at asco

Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mpdac) treated with elraglusib phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mpdac) treated with elraglusib
ACTU Ratings Summary
ACTU Quant Ranking